Showing 1765 results
-
Ad hoc release /Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced Accelerator Applications is a newly established subsidiary of Novartis Lutathera…
-
Press release /Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver…
-
Press release /Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of…
-
Featured News /
A new AI-enabled disease management tool in China aims to improve the lives of millions of patients with heart failure.
-
Press release /
Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises
Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in EuropeClinical data showed that use of Adakveo led to a… -
Featured News /
-
Press release /Objective is to provide patients with rapid cancer diagnostics and appropriate care First focus will be on Ethiopia, Uganda and Tanzania Cancer is on the rise in Africa, with more than 500,000…
-
Pulse Update /
-
Clinical Trials /
-
Clinical Trials /